Everyday drugs may slash COVID-19 hospitalizations, huge study hopes to prove

NCT ID NCT05504057

Recruiting now Prevention Sponsor: Consorci Sanitari de Terrassa Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This massive study is tracking over 140,000 people who already take antihistamines (allergy meds) or amantadine (a Parkinson's drug) to see if these drugs protect against COVID-19. Researchers will measure how many get infected, need hospital care, or develop long COVID. The goal is to find out if these common, cheap medications can reduce the severity of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: antihistamines and amantadine
What this could lead to: If it works, this could point toward a simple, low-cost way to prevent severe COVID-19 and long COVID in people already taking these medications.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is very large but early in terms of definitive proof.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital de Terrassa
RECRUITING

Terrassa, Barcelona, 08227, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hospital of Terrassa
RECRUITING

Terrassa, Barcelona, 08227, Spain

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.